MAPT and Alzheimer disease: Furthermore, we observed significantly lower wake bout lengths during the dark phase (1800–2100 hours) in both AD-tau–injected and noninjected APPPS1:E4 mice compared with APPPS1:E3 mice during the first week of SD (Supplemental Figure 4, C and D).